Author

E. Reuschel

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:deep learning· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

D. B. Weiner· 2 shared K. Schultheis· 2 shared M. Purwar· 2 shared A. Christensen-Quick· 1 shared A. Moore· 1 shared A. Sylvester· 1 shared C. Iffland· 1 shared C. Reed· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

D. B. Weiner

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drive rapid and potent immunogenicity capable of single-dose protection

K. Konrath, K. Liaw, Y. Wu, X. Zhu, S. Walker, Z. Xu, K. Schultheis, N. Chokkalingam, N. J. Tursi, J. Du, M. Sullivan, M. Purwar, A. Moore, V. Machado, I. Maricic, , D. W. Kulp

This study develops glycan-modified SARS-CoV-2 nanoparticle vaccines that induce potent neutralizing antibodies and single-dose protection against SARS-CoV-2 in multiple animal models.

bioRxiv · Apr 28, 2021Immunology

INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T cell Activity Against Global SARS-CoV-2 Variants

V. M. Andrade, A. Christensen-Quick, J. Agnes, J. Tur, C. Reed, R. Kalia, I. Marrero, D. Elwood, K. Schultheis, M. Purwar, E. Reuschel, T. McMullan, P. Pezzoli, K. Kraynyak, A. Sylvester, , K. E. Broderick

This study evaluates the efficacy of the INO-4800 DNA vaccine against SARS-CoV-2 variants, showing neutralizing antibodies and preserved T cell responses.

bioRxiv · Apr 14, 2021Immunology